679 related articles for article (PubMed ID: 18514425)
41. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
42. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
43. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
44. Managing patients on endocrine therapy: focus on quality-of-life issues.
Whelan TJ; Pritchard KI
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1056s-1060s. PubMed ID: 16467124
[TBL] [Abstract][Full Text] [Related]
45. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
Hayward RL; Dixon JM
Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
47. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
Baumgart J; Nilsson K; Evers AS; Kallak TK; Poromaa IS
Menopause; 2013 Feb; 20(2):162-8. PubMed ID: 22990756
[TBL] [Abstract][Full Text] [Related]
48. The importance of nonpharmacogenetic factors in endocrine therapy.
McCowan C; Thompson AM
Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
[TBL] [Abstract][Full Text] [Related]
49. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
50. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
51. Evolution of breast cancer treatments: current options and quality-of-life considerations.
Fallowfield LJ
Eur J Oncol Nurs; 2004; 8 Suppl 2():S75-82. PubMed ID: 15590318
[TBL] [Abstract][Full Text] [Related]
52. Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
Taira N; Iwata H; Hasegawa Y; Sakai T; Higaki K; Kihara K; Yamaguchi T; Ohsumi S; Shimozuma K; Ohashi Y
Breast Cancer Res Treat; 2014 May; 145(1):155-64. PubMed ID: 24692082
[TBL] [Abstract][Full Text] [Related]
53. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant hormonal therapy in early breast cancer.
Kumar S; Leonard RC
Oncology (Williston Park); 2005 Oct; 19(11):1425-8, 1433; discussion 1433-41, 1444-6. PubMed ID: 16370445
[TBL] [Abstract][Full Text] [Related]
55. Endocrine therapy in metastatic breast cancer.
Kimmick GG; Muss HB
Cancer Treat Res; 1998; 94():231-54. PubMed ID: 9587691
[TBL] [Abstract][Full Text] [Related]
56. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
Dellapasqua S; Castiglione-Gertsch M
Breast; 2005 Dec; 14(6):555-63. PubMed ID: 16188442
[TBL] [Abstract][Full Text] [Related]
58. Management of breast cancer in very young women.
Freedman RA; Partridge AH
Breast; 2013 Aug; 22 Suppl 2():S176-9. PubMed ID: 24074783
[TBL] [Abstract][Full Text] [Related]
59. Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Freedman OC; Verma S; Clemons MJ
Breast Cancer Res Treat; 2006 Oct; 99(3):241-7. PubMed ID: 16752075
[TBL] [Abstract][Full Text] [Related]
60. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK; Cheung YM; Yeo B; Grossmann M
J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
